Ribociclib adherence study with smart pill dispenser
Part of Cancer clinical trials.
This study is testing a new smart pill dispenser (called ReX) to help people with advanced breast cancer take their ribociclib medication regularly. You will answer simple questions about how you feel, and the device will track your medication use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with HR+ HER2- breast cancer that has spread to other parts of the body.
- You started taking ribociclib within the last 2 months.
- You are willing to fill out short questionnaires about your health and well-being during the study.
- You are able to use the ReX device (a special pill dispenser) that will be provided.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how well patients take ribociclib (a cancer-fighting drug) combined with hormone therapy for early-stage breast cancer, and monitors for any side effects. The goal is to understand real-world use and help patients stay on treatment safely.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This study compares how well breast cancer patients take their medication (ribociclib) with or without using a mobile app. It aims to see if the app helps patients stick to their treatment plan.
This study observes people with early-stage hormone receptor positive, HER2-negative breast cancer who are taking ribociclib (Kisqali) with hormone therapy after surgery. It aims to see how well the treatment works and how safe it is in real life.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
Hear when a new Any Solid Oral Medication trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.